Document is current

Article History

Received: 11 September 2025

Accepted: 31 December 2025

First Online: 10 January 2026

Declarations

:

: The authors declare no competing interests.

: This study was approved by the ethics committee of the First Affiliated Hospital of Nanchang University (No. 2023007-064).

: The purpose of this study is to evaluate the immunomodulatory effect of spleen aminopeptide-containing hydrogels on recurrent respiratory tract infections in children. The project strictly abides by ethical norms, and the legal guardians of all subjects have signed written informed consent. The main contents are as follows: 1. Voluntary participation: The guardians have fully understood the purpose, process and potential risks of the research. The guardians voluntarily agreed to the child’s participation, and know that they could quit at any time. 2. Risks and benefits: We have known the possible risks (such as slight discomfort in blood collection and adverse reactions related to hydrogels) and potential benefits (which may improve immunity). There may be no direct personal benefits from understanding the research results. 3. Privacy protection: Personal information of the subjects has been de-identified, and only the research team can access it with authorization. 4. Protection of children’s rights and interests: In addition to the guardian’s consent, children over 8 years old also signed the informed consent form. 5. Ethical review: This study has been approved by the Ethics Committee. It is hereby confirmed that the informed consent procedure of legal guardians of all subjects has been completed.